NSCLC (ADVANCED NON-SMALL CELL LUNG CANCER)
Clinical trials for NSCLC (ADVANCED NON-SMALL CELL LUNG CANCER) explained in plain language.
Never miss a new study
Get alerted when new NSCLC (ADVANCED NON-SMALL CELL LUNG CANCER) trials appear
Sign up with your email to follow new studies for NSCLC (ADVANCED NON-SMALL CELL LUNG CANCER), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New radiation combo aims to shrink lung tumors faster and safer
Disease control Not yet recruitingThis study tests a new way to give radiation for advanced non-small cell lung cancer. It combines high and low doses of radiation with chemotherapy and immunotherapy to shrink tumors quickly while lowering the risk of lung inflammation. About 70 adults with stage III or select st…
Matched conditions: NSCLC (ADVANCED NON-SMALL CELL LUNG CANCER)
Phase: PHASE2 • Sponsor: Fudan University • Aim: Disease control
Last updated May 26, 2026 05:04 UTC
-
Lung cancer drug shows promise in Later-Line treatment
Disease control Not yet recruitingThis study examines the effectiveness and safety of anlotinib, a targeted therapy, for people with advanced non-small cell or small cell lung cancer who have already tried anlotinib and it stopped working. Researchers will review medical records from multiple hospitals to see if …
Matched conditions: NSCLC (ADVANCED NON-SMALL CELL LUNG CANCER)
Sponsor: Henan Cancer Hospital • Aim: Disease control
Last updated May 26, 2026 05:04 UTC
-
New hope for hard-to-treat lung cancer: targeted drug combo enters phase 2 trial
Disease control Not yet recruitingThis study tests a new drug called GFH375, alone or with other medicines, in people with advanced non-small cell lung cancer that has a specific KRAS G12D mutation. About 90 participants will be split into three groups to see which treatment works best and is safe. The goal is to…
Matched conditions: NSCLC (ADVANCED NON-SMALL CELL LUNG CANCER)
Phase: PHASE2 • Sponsor: Genfleet Therapeutics (Shanghai) Inc. • Aim: Disease control
Last updated May 26, 2026 05:03 UTC
-
New care plan aims to tame lung cancer Drug's side effects
Disease control Not yet recruitingThis study tests a special care plan (CEPM) to help manage side effects like skin rash and infusion reactions in people with advanced EGFR-mutated lung cancer who are taking the drug amivantamab. About 122 Chinese adults will join to see if this plan improves their quality of lif…
Matched conditions: NSCLC (ADVANCED NON-SMALL CELL LUNG CANCER)
Phase: PHASE4 • Sponsor: Shanghai Pulmonary Hospital, Shanghai, China • Aim: Disease control
Last updated May 26, 2026 05:01 UTC
-
New hope for lung cancer patients with brain tumors: drug combo trial launches
Disease control Not yet recruitingThis study tests a new combination of drugs (Sac-TMT plus a third-generation EGFR-TKI) with or without radiation for people with a specific type of lung cancer that has spread to the brain and stopped responding to previous treatment. About 45 adults with EGFR-mutated non-squamou…
Matched conditions: NSCLC (ADVANCED NON-SMALL CELL LUNG CANCER)
Phase: PHASE2 • Sponsor: Zhejiang Cancer Hospital • Aim: Disease control
Last updated May 26, 2026 04:36 UTC
-
New hope for bulky lung cancer: drug-radiation combo tested in major trial
Disease control Not yet recruitingThis study tests whether adding the drug adebrelimab to standard chemoradiotherapy helps people with a large, advanced lung cancer that cannot be removed by surgery. About 204 adults aged 18-75 with stage III non-small cell lung cancer will take part. The main goal is to see if t…
Matched conditions: NSCLC (ADVANCED NON-SMALL CELL LUNG CANCER)
Phase: PHASE3 • Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences • Aim: Disease control
Last updated May 26, 2026 04:36 UTC
-
Immune booster: NK cells join standard care for advanced cancers
Disease control Not yet recruitingThis early-phase study tests whether adding donor natural killer (NK) cells to standard maintenance therapy can safely help control advanced solid tumors, including non-small cell lung cancer and colorectal cancer. About 20 adults aged 18-75 will receive NK cell infusions alongsi…
Matched conditions: NSCLC (ADVANCED NON-SMALL CELL LUNG CANCER)
Phase: PHASE1, PHASE2 • Sponsor: BOE Technology Group Co., Ltd. • Aim: Disease control
Last updated May 22, 2026 14:03 UTC
-
New combo therapy aims to stop lung cancer return after surgery
Disease control Not yet recruitingThis study is for people with stage III non-small cell lung cancer who had chemotherapy and immunotherapy before surgery, then surgery to remove the tumor, but still had cancer in their lymph nodes. Researchers want to see if adding targeted radiation to the lymph nodes after sur…
Matched conditions: NSCLC (ADVANCED NON-SMALL CELL LUNG CANCER)
Phase: PHASE2 • Sponsor: Shanghai Zhongshan Hospital • Aim: Disease control
Last updated May 22, 2026 14:01 UTC
-
New combo aims to revive immune attack on tough lung cancers
Disease control Not yet recruitingThis study tests a new two-drug combination for people with advanced non-small cell lung cancer whose disease got worse after standard immunotherapy and chemotherapy. The drugs—gemcitabine (a chemotherapy) and ivonescimab (a targeted therapy)—are given together to try to shrink t…
Matched conditions: NSCLC (ADVANCED NON-SMALL CELL LUNG CANCER)
Phase: PHASE2 • Sponsor: Swiss Cancer Institute • Aim: Disease control
Last updated May 20, 2026 11:57 UTC
-
New combo therapy aims to slow advanced lung cancer
Disease control Not yet recruitingThis study tests whether adding an experimental drug (nogapendekin alfa inbakicept) to standard chemotherapy and immunotherapy can help people with advanced non-small cell lung cancer live longer without their cancer growing. About 494 adults with stage IV lung cancer who have no…
Matched conditions: NSCLC (ADVANCED NON-SMALL CELL LUNG CANCER)
Phase: PHASE3 • Sponsor: ImmunityBio, Inc. • Aim: Disease control
Last updated May 20, 2026 11:54 UTC
-
Lung cancer study aims to decode immune secrets
Knowledge-focused Not yet recruitingThis study will collect and analyze tumor samples from 500 people with advanced non-small cell lung cancer to see how immune markers and gene activity relate to treatment response. Participants give biopsies before and during immunochemotherapy. The goal is to learn, not to test …
Matched conditions: NSCLC (ADVANCED NON-SMALL CELL LUNG CANCER)
Sponsor: Technische Universität Dresden • Aim: Knowledge-focused
Last updated May 22, 2026 13:55 UTC